Fig. 3.

Antibody titres and neutralising capacity of SARS-CoV-2 Omicron in relation to number of vaccine doses and SARS-CoV-2 infection (COVID-19). Ab titres (A) and neutralizing capacity (B) of SARS-CoV-2 variants at the 12-month timepoint (left) showing individual samples as blue connected lines, and mean value across SARS-CoV-2 variants (orange line), and correlation matrices (Pearson correlation) of Ab titres for analysed SARS-CoV-2 variants (right) with correlations between Omicron-variants and non-Omicron variants in highlighted (black rectangle) areas. (C) Box plot showing neutralisation of individual samples, grouped based on COVID-19 status as defined by prior positive COVID-19 test and/or Nucleocapsid Ab titres >5000 AU/ml. Neutralisation was quantified using V-PLEX Serology Panels with an ACE2 surrogate virus neutralisation kit (Meso Scale Diagnostics, MSD). (D–G) Neutralisation of Spike Wu-Hu.1 and Spike BA.1 following three or four vaccine doses in each patient subgroup, ordered by their respective mean neutralizing capacity. Only subgroups with more than five recorded samples are displayed. Statistical tests performed were Mann–Whitney with Bonferroni correction for multiple comparisons. The star annotation (∗) indicates statistical significance at a p-value threshold of 0.05 (or ∗∗ for p < 0.01, ∗∗∗ for p < 0.001, ∗∗∗∗ for p < 0.0001). For sample sizes, please see Table 1. Whiskers for all boxplots represents 1.5× IQR.